Exercise for Advanced Prostate Cancer: a Multicomponent Feasibility Trial

Prostate Cancer Metastatic Clinical Trial

— EXACT  

Official title:

Exercise for Advanced Prostate Cancer: a Multicomponent Feasibility Trial in Men With Metastatic Castrate-Resistant Prostate Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03658486
• Other study ID #: B18/15
• Status: Completed
• Phase: N/A
• Start date: February 19, 2019
• Est. completion date: August 31, 2022

Study information

• Verified date: February 2024
• Source: Queen's University, Belfast
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This feasibility study will investigate whether men with metastatic prostate cancer can take part in and progress through a home-based exercise program. This study will evaluate the effects of exercise on a range of disease and treatment-related outcomes.

Description:

This 12 week multicomponent, tailored, progressive program will consist of both moderate intensity walking and strengthening exercises at home. This single centre, single arm study will incorporate a behavioural change consultation at baseline and weekly behavioural support throughout. This study will follow-up patients at 24 weeks to determine exercise maintenance. Outcome measures will be completed at baseline, 12 and 24 weeks. A qualitative evaluation will be conducted after the 24 week follow-up to determine impact, patient experience and measures that might assist in refining the program.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: August 31, 2022
• Est. primary completion date: August 31, 2022
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically documented adenocarcinoma of the prostate with progressive systemic metastatic disease despite castrate levels of testosterone (<50ng/dL).

• At enrolment, patients must have demonstrated progressive disease since the most recent change in therapy.

• Patients must be on ADT with a GnRH agonist/antagonist or prior bilateral orchiectomy. All patients must be on ADT during the study period.

• = 4 weeks since last surgery and fully recovered.

• No known contraindications to moderate intensity exercise such as (but not limited to) brain metastases, acute congestive heart failure, unstable angina, serious or non-healing wound, peripheral neuropathy greater than or equal to Grade 3. Recent myocardial infarction.

• Age = 18 years.

• ECOG performance status 0-2.

• Medical clearance by treating clinician.

Exclusion Criteria:

• Men currently exceeding ACSM recommended exercise guidelines (150 mins of moderate and/or 60 mins of high intensity exercise per week).

• Men with brain metastases.

• Men with a currently active second malignancy other than non-melanoma skin cancer.

• Congestive heart failure or recent serious cardiovascular event.

• Chest pain brought on by physical activity.

Related Conditions & MeSH terms

• Castration-resistant Prostate Cancer
• Prostate Cancer Metastatic
• Prostatic Neoplasms

Intervention

Other:
• Exercise
Exercise programs will be individually tailored to the capabilities of each participant and gradually progressed accordingly. Each patient will be assigned a moderate intensity walking and strengthening program to complete at home. At baseline, 12 and 24 weeks patients will wear an accelerometer to determine activity levels. At these time points, patients will also complete a physical fitness assessment (timed sit-to-stand and six minute walking tests) and a range of quality of life questionnaires. At baseline, patients will receive a behaviour change consultation and continued support throughout the intervention. Each patient will receive a pedometer during the home-based, unsupervised regime to monitor step count and they are expected to complete a daily physical activity diary. Upon completion of the 24 week follow-up, patients will be invited to partake in semi-structured interviews to determine the effectiveness of the program and their experience throughout.

Locations

Country	Name	City	State
United Kingdom	Northern Ireland Cancer Centre, Belfast City Hospital	Belfast

Sponsors (2)

Lead Sponsor	Collaborator
Queen's University, Belfast	HSC Public Health Agency

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility - recruitment.	The number of participants that agree to participate or are excluded.	At baseline.
Primary	Feasibility - adherence to the exercise intervention.	Determine the percentage of patients adhering to the program and the weekly behavioral consultation sessions.	Throughout the 24 week study period.
Primary	Feasibility - attrition rates.	The number of patients that withdraw.	Throughout the 24 week study period.
Primary	Feasibility - safety / adverse events.	Any safety / adverse events, in general or in relation to the exercise program, will be documented by the research team.	Monitored throughout the 24 week study period.
Primary	Feasibility - patient experience.	Determined by qualitative evaluation, using semi-structured interviews, to assess experiences, accessibility and acceptability of the exercise intervention.	Following the study conclusion at 24 weeks.
Secondary	Anthropometric assessment.	Height will be measured in cm and body weight in kg, which will be combined to report BMI in kg/m(squared).	At baseline, 12 and 24 weeks.
Secondary	Hip and waist circumference analysis.	Hip and waist circumference will be measured in cms.	At baseline, 12 and 24 weeks.
Secondary	Functional ability assessment.	The amount of repetitions achieved during a 30 second sit-to-stand test will be recorded.	At baseline, 12 and 24 weeks.
Secondary	Physical fitness assessment.	Distance covered in meters during a six minute walk test will be recorded.	At baseline, 12 and 24 weeks.
Secondary	Objectively measure of physical activity levels.	Patients will wear an accelerometer for 7 full days.	At baseline, 12 and 24 weeks.
Secondary	Perceived physical activity levels.	Patients will complete an International Physical Activity Questionnaire (IPAQ-SF). This questionnaire will comprise 4 generic items to obtain comparable health-related physical activity. Patients will detail the number of days, hours and minutes that they undertake (1) vigorous exercise (2) moderate exercise (3) walking exercise and (4) sitting. Total physical activity will be generated and monitored for improvement or decline.	At baseline, 12 and 24 weeks.
Secondary	Cancer-related fatigue by questionnaire.	Fatigue will be measured by the Functional Assessment of Cancer Therapy - Fatigue (FACIT-Fatigue) questionnaire. Patients will score several fatigue items over the past 7 days on a scale (0 = not at all; 4 = very much), generating a total (0 - 52) with higher scores linked to greater quality of life.	At baseline, 12 and 24 weeks.
Secondary	Quality of life will be measured using a questionnaire.	Quality of life will be measured by the Functional Assessment of Cancer Therapy - Prostate (FACT-P) questionnaire. Patients will score a series of questions (0 = not at all; 4 = very much) in five sections (physical well-being; social/family well-being; emotional well-being; functional well-being; additional concerns) for the past 7 days. Higher scores will suggest better quality of life.	At baseline, 12 and 24 weeks.
Secondary	Quality of life will be measured using questionnaires.	Quality of life will be measured by the EuroQOL Five Dimension Questionnaire (EQ5D). Patients will select a level of difficulty (I have no - I have extreme) on that particular days health for mobility, self-care, usual activities, pain / discomfort and anxiety / depression. Patients will then rate 'how good' or 'how bad' their health is on that day using a 100 point scale (0 = worst health you can imagine; 100 = best health you can imagine).	At baseline, 12 and 24 weeks.
Secondary	Pain will be measured through a questionnaire.	Bone pain will be monitored using the Brief Pain Inventory Short Form (BPI-SF).	At baseline, 12 and 24 weeks.